NPI: 1982015863 · NEWPORT NEWS, VA 23601 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 05/14/2014
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 05/14/2014 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,887 | $34K |
| 2019 | 5,787 | $107K |
| 2020 | 5,012 | $78K |
| 2021 | 2,910 | $87K |
| 2022 | 235 | $19K |
| 2023 | 131 | $38K |
| 2024 | 495 | $34K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 12,014 | 553 | $216K |
| 90945 | 1,790 | 88 | $156K | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 1,039 | 143 | $24K |
| J1756 | Injection, iron sucrose, 1 mg | 17 | 12 | $47.58 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 24 | 12 | $31.37 |
| 83970 | 128 | 79 | $22.01 | |
| 82728 | 178 | 116 | $15.10 | |
| 83550 | 291 | 199 | $12.84 | |
| 83540 | 290 | 198 | $9.52 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 30 | 12 | $8.26 |
| 85041 | 274 | 184 | $5.19 | |
| 85048 | 274 | 184 | $4.62 | |
| A4657 | Syringe, with or without needle, each | 108 | 64 | $0.06 |